Tomoyuki Fujita

Cardiac surgeon
Tokyo Medical and Dental University - Tokyo, Japan

Latest contributions

How to optimise the patient outcomes - Key considerations for the small body population

08 Feb 2025 – From PCR Tokyo Valves 2025

Explore the latest strategies for optimizing outcomes in Asian and international patients with small body size. Through case presentations, surgical experiences, and the latest data on device performance, gain valuable insights into treating aortic stenosis more effectively. Discover how these advancements can enhance patient care and...

How to optimise the patient outcomes - Key considerations for the small body population

Future devices for structural heart interventions

08 Feb 2025 – From PCR Tokyo Valves 2025

Get a glimpse into the future of structural heart interventions! This PCR Tokyo Valves 2025 session dives into the latest innovations in imaging and explores groundbreaking devices for mitral and tricuspid valve treatments. Watch as experts discuss how these advancements are set to reshape clinical practice.

Future devices for structural heart interventions

TAVI in bicuspid anatomy

18 Feb 2024 – From PCR Tokyo Valves 2024

Delve into the complexities of TAVI within bicuspid anatomy through this selection of cases: learn about the challenges and techniques involved in overcoming the horizontal aorta, explore how to size  the transcatheter aortic valve in severely calcified bicuspid anatomy, and more!

Late-Breaking Trial session

17 Feb 2024 – From PCR Tokyo Valves 2024

Explore pivotal findings from registries and studies, including the OCEAN-TAVI Registry on PPM prevalence in Asian TAVR patients, SIL-TAVI Registry insights on TAVI outcomes in cancer patients, the EXPAND G4 study's outcomes for Japanese MitraClip G4 recipients, and TRISTAR study's 30-day results on K-Clip for tricuspid...

Late-Breaking Trial session

The optimal first valve choice for patients with aortic stenosis - Key considerations for lifetime management

17 Feb 2024 – From PCR Tokyo Valves 2024

This session tackles the pressing topic of TAVI's success in treating aortic stenosis, particularly in younger patients, and the ensuing questions regarding device durability, potential follow-up procedures, and the interplay between TAVI and surgical options. The aim is to ensure optimal decision-making that prioritizes patient welfare...

Selection of the 2023 best abstracts

19 Feb 2023 – From PCR Tokyo Valves 2023

Watch this session to discover the best cases and abstracts unveiled at PCR Tokyo Valves 2023, covering topics such as transcatheter aortic valve implantation impact, cerebral protection efficacy, and post-TAVI aortic regurgitation quantification.

TAVI in a patient with heavily calcified valve anatomy - LIVE case

18 Feb 2023 – From PCR Tokyo Valves 2023

An 80-year-old male with chronic kidney disease and interstitial pneumonia treated under steroids presented a symptomatic severe aortic stenosis with massive calcifications on the valves and only on the valves (not the LVOT).
Watch the operators implant a Sapien 3 23 mm (-1cc) with a predilatation (Balloon...

TAVI in a patient with heavily calcified valve anatomy

Treatment of aortic stenosis in patients with longer life expectancy: case-based heart team discussion

26 Sep 2021 – From PCR Tokyo Valves 2021

Watch this session with a case-based heart team discussion to learn more about the treatment of aortic stenosis in patients with longer life expectancy: discover what the 2021 guidelines say about patient selection, what should be considered for patients with longer life expectancy, and how to optimise procedural outcome.

Treatment of aortic stenosis in patients with longer life expectancy: case-based heart team discussion

How should aortic stenosis be treated in the modern era and what is the role of the heart team?

15 Feb 2020 – From PCR Tokyo Valves 2020

Consult this session to gain insight into the current status of aortic stenosis treatment around the world, to learn more about the patient and treatment selection by the Heart Team, and to discover how the patient pathway's optimization may facilitate the increasing demand for TAVR.

How should aortic stenosis be treated in the modern era and what is the role of the heart team?